Cargando…

Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the “Programmed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinoma”

Detalles Bibliográficos
Autores principales:	Eccher, Albino, Fontanini, Gabriella, Fusco, Nicola, Girolami, Ilaria, Graziano, Paolo, Rocco, Elena Guerini, Martini, Maurizio, Morbini, Patrizia, Pantanowitz, Liron, Parwani, Anil, Pisano, Anna Maria, Troncone, Giancarlo, Vigliar, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112335/ https://www.ncbi.nlm.nih.gov/pubmed/34012705 http://dx.doi.org/10.4103/jpi.jpi_63_20

Ejemplares similares

Digital Slide Assessment for Programmed Death-Ligand 1 Combined Positive Score in Head and Neck Squamous Carcinoma: Focus on Validation and Vision
por: Eccher, Albino, et al.
Publicado: (2021)

Program death ligand‐1 immunocytochemistry in lung cancer cytological samples: A systematic review
por: Satturwar, Swati, et al.
Publicado: (2022)

Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study
por: Guerini Rocco, Elena, et al.
Publicado: (2022)

Relevance of the College of American Pathologists guideline for validating whole slide imaging for diagnostic purposes to cytopathology
por: Antonini, Pietro, et al.
Publicado: (2022)

The histopathological diagnosis of atypical meningioma: glass slide versus whole slide imaging for grading assessment
por: Ammendola, Serena, et al.
Publicado: (2020)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

The Landscape of Digital Pathology in Transplantation: From the Beginning to the Virtual E-Slide
por: Girolami, Ilaria, et al.
Publicado: (2019)

Innovation in Transplantation: The Digital Era
por: Eccher, Albino, et al.
Publicado: (2018)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
por: Goto, Hiroyuki, et al.
Publicado: (2021)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
por: Zhang, Yan, et al.
Publicado: (2011)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
por: Liu, Xiaojun, et al.
Publicado: (2016)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
por: Liu, Qiang, et al.
Publicado: (2017)

Programmed death-ligand 1 expression in rectal cancer
por: Jomrich, G., et al.
Publicado: (2016)

Status of programmed death-ligand 1 expression in sarcomas
por: Park, Hyung Kyu, et al.
Publicado: (2018)

Technical and Diagnostic Issues in Whole Slide Imaging Published Validation Studies
por: Rizzo, Paola Chiara, et al.
Publicado: (2022)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
por: Rozali, Esdy N., et al.
Publicado: (2012)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma
por: Chandrasekaran, Deepika, et al.
Publicado: (2019)

Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti–programed death-ligand 1 (Avelumab)
por: Gill, Amanda L., et al.
Publicado: (2016)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
por: Wang, Shiqiang, et al.
Publicado: (2020)

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity
por: Niedźwiedzka-Rystwej, Paulina, et al.
Publicado: (2022)

PD‐L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside
por: Nocini, Riccardo, et al.
Publicado: (2022)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis
por: Chang, Katherine, et al.
Publicado: (2014)

Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
por: Kamata, Toshiko, et al.
Publicado: (2016)

Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
por: Zhou, Tingting, et al.
Publicado: (2018)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy
por: Castellanos, Emily H., et al.
Publicado: (2017)

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
por: Zhao, Bin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8i9nrl9r8cd898n5rr8re45102